Non-opioid pain therapies are entering an unprecedented era, marked by the landmark FDA approval of Vertex’s Journavx and a ...

The U.S. Food and Drug Administration (FDA) has approved Journavx, the first opioid-free prescription drug for moderate to ...

RBC Capital notes that the clinical review documents associated with Sector Perform-rated Vertex Pharmaceuticals (VRTX)’ recent approval of ...

On January 30, the U.S. Food and Drug Administration approved Journavx (suzetrigine) 50 milligram oral tablets, a first-in-class non-opioid ...

(NASDAQ:VRTX) has recently achieved a significant milestone with the FDA's approval of JOURNAVX(suzetrigine), a novel ...

The US FDA has approved Journavx, a new pain reliever without the risks for addiction or overdose linked to drugs like Vicodin and OxyContin.

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) has approved JOURNAVX™ (suzetrigine), an oral, non-opioid, highly selective ...

There are plenty of great investment alternatives in the healthcare sector. You won't need a boatload of money to get started ...

Avtozma, the third biosimilar to Actemra, has received FDA approval for multiple inflammatory diseases and COVID-19, potentially expanding treatment access for patients. Suzetrigine (Journavx ...

On January 30, 2025, the US FDA approved Journavx (suzetrigine) 50mg oral tablets to use in the treatment of moderate to severe acute pain, making it the first non-opioid analgesic of its class to ...

While medications such as methadone, buprenorphine, and naltrexone are FDA-approved for treating opioid use disorder, they ...